We show for the first time that fenretinide is active against human osteosarcoma in vitro, at concentrations identical to or lower than those detectable in patient’s plasma during chemopreventive clinical trials for breast cancer or head and neck carcinoma. Results show for the first time that caveolin-1 may be a novel molecular target for fenretinide therapeutic activity in this tumor, where its protein expression is downregulated by the drug.
Fenretinide is active in osteosarcoma in vitro by down-regulation of caveolin-1 expression / Gasperi-Campani A.; Baiocchi D.; Marti G.; Roncuzzi L.. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - STAMPA. - 18 SUPPL 4:(2007), pp. 40-40. (Intervento presentato al convegno 5th international Symposium on Targeted Anticancer Therapies tenutosi a Amsterdam nel 8-10 marzo 2007).
Fenretinide is active in osteosarcoma in vitro by down-regulation of caveolin-1 expression.
GASPERI CAMPANI, ANNA;BAIOCCHI, DANIELA;RONCUZZI, LAURA
2007
Abstract
We show for the first time that fenretinide is active against human osteosarcoma in vitro, at concentrations identical to or lower than those detectable in patient’s plasma during chemopreventive clinical trials for breast cancer or head and neck carcinoma. Results show for the first time that caveolin-1 may be a novel molecular target for fenretinide therapeutic activity in this tumor, where its protein expression is downregulated by the drug.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
